HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.

AbstractBACKGROUND & AIMS:
Crohn's disease is a chronic debilitating disease characterized by severe T helper cell (Th)1-driven inflammation of the colon partially caused by a loss of immune tolerance against mucosal antigens. The use of regulatory dendritic cells (DCs) with the capacity to induce regulatory T cells has been proposed recently for the treatment of Crohn's disease in a strategy to restore immune tolerance. Vasoactive intestinal peptide is an immunomodulatory neuropeptide that induces regulatory DCs. The aim of this study was to investigate the therapeutic effect of vasoactive intestinal peptide-induced regulatory DCs (DC(VIP)) in a murine model of colitis.
METHODS:
We examined the therapeutic action of DC(VIP) in the colitis induced by intracolonic administration of trinitrobenzene sulfonic acid, evaluating diverse clinical signs of the disease including weight loss, diarrhea, colitis, and histopathology. We also investigated the mechanisms involved in the potential therapeutic effect of DC(VIP), such as inflammatory cytokines and chemokines, Th1-type response, and the generation of regulatory T cells.
RESULTS:
DC(VIP) injection significantly ameliorated the clinical and histopathologic severity of colitis, abrogating body weight loss, diarrhea, and inflammation, and increasing survival. The therapeutic effect was associated with down-regulation of both inflammatory and Th1-driven autoimmune response, by regulating a wide spectrum of inflammatory mediators directly through activated macrophages, and by generating interleukin-10-secreting regulatory T cells with suppressive capacity on autoreactive T cells.
CONCLUSIONS:
The possibility to generate/expand ex vivo regulatory DC(VIP) opens new therapeutic perspectives for the treatment of Crohn's disease in human beings, and may minimize the dependence on nonspecific immunosuppressive drugs used currently for autoimmune disorders.
AuthorsElena Gonzalez-Rey, Mario Delgado
JournalGastroenterology (Gastroenterology) Vol. 131 Issue 6 Pg. 1799-811 (Dec 2006) ISSN: 0016-5085 [Print] United States
PMID17087944 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Transforming Growth Factor beta
  • Interleukin-10
  • Vasoactive Intestinal Peptide
  • Trinitrobenzenesulfonic Acid
Topics
  • Animals
  • Autoimmunity
  • CD4-Positive T-Lymphocytes (metabolism, pathology)
  • Cell Transplantation
  • Cells, Cultured
  • Colitis (chemically induced, metabolism, pathology, prevention & control)
  • Dendritic Cells (immunology, metabolism)
  • Disease Models, Animal
  • Immune Tolerance
  • Immunotherapy (methods)
  • Interleukin-10 (metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Th1 Cells (metabolism, pathology)
  • Transforming Growth Factor beta (metabolism)
  • Trinitrobenzenesulfonic Acid
  • Vasoactive Intestinal Peptide (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: